• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Athersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    10/30/23 4:30:14 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHX alert in real time by email
    athx20231030_8k.htm
    false 0001368148 0001368148 2023-10-30 2023-10-30
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
     
    Date of report (Date of earliest event reported): October 30, 2023
     
    ATHERSYS, INC.
    ATHERSYS, INC / NEW
    (Exact Name of Registrant as Specified in Charter) 
     

     
    Delaware
    001-33876
    20-4864095
    (State or Other Jurisdiction
    of Incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)
     
     
    3201 Carnegie Avenue,  Cleveland,   Ohio
     
    44115-2634
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: (216) 431-9900
     
     
    (Former Name or Former Address, if Changed Since Last Report)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol
    Name of each exchange on which registered
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company  ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
     


     
     

     
     
    Item 1.01         Entry into a Material Definitive Agreement
     
    On October 30, 2023, Athersys, Inc. (the “Company”) entered into an offer letter (the “Letter Agreement”) with a holder  (“Holder”) of the Company’s common stock purchase warrants issued on October 16, 2023 (the “Existing Warrants”) to (1) reduce the exercise price of the Existing Warrants from $0.1395 to $0.01 per share (the “Reduced Exercise Price”), (2) issue to the Holder new common stock purchase warrants (the “New Warrants”) to purchase up to 20,000,000 shares of the Company’s common stock at an exercise price of $0.01 per share; and (3) make the Existing Warrants immediately exercisable.
     
    Pursuant to the Letter Agreement, the Holder agreed to (A) reduce the period of the subsequent equity sale restrictions contained in Section h)(i) of Annex A to the warrant exercise inducement offer letter dated October 11, 2023 between the Holder and the Company (the “October 11, 2023 Letter”) from 60 days to 30 days; (B) reduce the applicable period in each and all of the provisions relating to restrictions on the Company (or any of its subsidiaries) involving a “Variable Rate Transaction” (as such term, or a term of similar meaning, is defined in the applicable document) so that each such period terminates on March 1, 2024 in all stock purchase agreements, related letter agreements, and all other related agreements with the Holder; and (C) vote as set forth below in connection with a Fundamental Transaction.
     
    The Holder agreed that upon the occurrence of a Fundamental Transaction (as defined in the New Warrants), if the Holder holds any shares of the Company’s common stock and a stockholder vote is required for such Fundamental Transaction, then the Holder agrees to vote all shares of its common stock that it holds as of any such record date that may be taken the vote of stockholders that are entitled to vote on such Fundamental Transaction in accordance with the recommendations of the Company’s board of directors.
     
    We also agreed to file a registration statement (the “Registration Statement”) on Form S-1 (or other appropriate form) providing for the resale of the shares of common stock issuable upon exercise of the New Warrants (the “New Warrant Shares”), on or before November 12, 2023, and to use commercially reasonable efforts to have such Resale Registration Statement declared effective by the U.S. Securities and Exchange Commission (the “SEC”) within 90 days following the date of filing with the SEC and to keep the Resale Registration Statement effective at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares.
     
    In addition, on October 30, 2023, the Company and the Holder entered into an Amendment to Series A Common Stock Purchase Warrants (the “Warrant Amendment”) which amended the Existing Warrants to reflect (i) the Reduced Exercise Price, (ii) that the Existing Warrants are now immediately exercisable, and (iii) that the Existing Warrants will terminate on October 30, 2028. The Warrant Amendment is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description of the Warrant Amendment is qualified in its entirety by reference to such exhibit.
     
    New Warrant Terms
     
    The following summary of certain terms and provisions of the New Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of the New Warrants, the form of which is filed as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated herein by reference. The following description of the New Warrants is qualified in its entirety by reference to such exhibit.
     
    Exercise Period and Dilution
     
    Each New Warrant will have an exercise price equal to its applicable Reduced Exercise Price. The New Warrants are immediately exercisable on the date of issuance and may be exercised for a period of five years therefrom. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate proportional adjustment in the event of share dividends, share splits, reorganizations or similar events affecting our common stock and the exercise price.
     
    Exercisability
     
    The New Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice and, within the earlier of (i) two trading days and (ii) the number of trading days comprising the standard settlement period with respect to the common stock as in effect on the date of delivery of the notice of exercise thereafter, payment in full for the number of shares of common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder may not exercise any portion of the New Warrant to the extent that the holder, together with its affiliates and any other persons acting as a group together with any such persons, would own more than 4.99% (or, at the election of the purchaser, 9.99%) of the number of shares of common stock outstanding immediately after exercise (the “Beneficial Ownership Limitation”); provided that a holder with a Beneficial Ownership Limitation of 4.99%, upon notice to us and effective  61 days after the date such notice is delivered to us, may increase the Beneficial Ownership Limitation so long as it in no event exceeds 9.99% of the number of shares of common stock outstanding immediately after exercise.
     
    Cashless Exercise
     
    If, at the time a holder exercises its New Warrants, a registration statement registering the issuance of the shares of common stock underlying the New Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may only exercise its New Warrants (either in whole or in part), at such time by means of a cashless exercise in which the holder shall be entitled to receive upon such exercise the net number of shares of common stock determined according to a formula set forth in the New Warrants, which generally provides for a number of shares of common stock equal to (A) (1) the volume weighted average price on (x) the trading day preceding the notice of exercise, if the notice of exercise is executed and delivered on a day that is not a trading day or prior to the opening of “regular trading hours” on a trading day or (y) the trading day of the notice of exercise, if the notice of exercise is executed and delivered after the close of “regular trading hours” on such trading day, or (2) the bid price on the day of the notice of exercise, if the notice of exercise is executed during “regular trading hours” on a trading day and is delivered within two hours thereafter, less (B) the exercise price, multiplied by (C) the number of shares of common stock the New Warrant was exercisable into, with such product then divided by the number determined under clause (A) in this sentence.
     
    Fractional Shares
     
    No fractional shares of common stock will be issued upon the exercise of the New Warrants. Rather, we will, at our election, and in lieu of the issuance of such fractional share, either (i) pay cash in an amount equal to such fraction multiplied by the exercise price or (ii) round up to the next whole share issuable upon exercise of the New Warrant.
     
    Transferability
     
    Subject to applicable laws, a New Warrant may be transferred at the option of the holder upon surrender of the New Warrant to us together with the appropriate instruments of transfer and funds sufficient to pay any transfer taxes payable upon such transfer.
     
     

     
    Market
     
    There is no trading market available for the New Warrants on any securities exchange or nationally recognized trading system. We do not intend to list the New Warrants on any securities exchange or nationally recognized trading system. The shares of common stock issuable upon exercise of the New Warrants are currently quoted on the Pink Open Market tier operated by OTC Markets Group, Inc. (the “OTC Pink”) under the symbol “ATHX.”
     
    Rights as a Stockholder
     
    Except as otherwise provided in the New Warrants or by virtue of such holder’s ownership of shares of the Company’s common stock, the holders of the New Warrants do not have the rights or privileges of holders of the Company’s common stock, including any voting rights, until they exercise their New Warrants.
     
    Fundamental Transaction
     
    In the event of a fundamental transaction, as described in the New Warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding shares of common stock, the holders of the New Warrants will be entitled to receive upon exercise of the New Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the New Warrants immediately prior to such fundamental transaction. Additionally, in the event of a fundamental transaction, we or any successor entity will, at the option of the holder of a New Warrant exercisable at any time concurrently with or within 30 days after the consummation of the fundamental transaction (or, if later, the date of the public announcement thereof), purchase the New Warrant from the holder by paying to the holder an amount of consideration equal to the value of the remaining unexercised portion of such New Warrant on the date of consummation of the fundamental transaction based on the Black-Scholes option pricing model, determined pursuant to a formula set forth in the New Warrants. The consideration paid to the holder will be the same type or form of consideration that was offered and paid to the holders of shares of common stock in connection with the fundamental transaction; provided that if no such consideration was offered or paid, the holders of common stock will be deemed to have received common stock of the successor entity in such fundamental transaction for purposes of this provision of the New Warrants.
     
    Item 3.02         Unregistered Sales of Equity Securities
     
    The Company will issue the New Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2) thereof. The New Warrants and the New Warrant Shares are not registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. The description of the New Warrants under Item 1.01 of this Form 8-K is incorporated by reference herein.
     
    Item 9.01         Financial Statements and Exhibits.
     
     
    (d)    Exhibits.
     
    Exhibit No.
     
    Description
    4.1
     
    Form of New Warrant.
    10.1   Form of Letter Agreement.
    10.2   Warrant Amendment.
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: October 30, 2023
     
    ATHERSYS, INC.
         
     
    By:
    /s/ Daniel Camardo
       
    Daniel Camardo
    Chief Executive Officer and Duly Authorized Officer
     
     
    Get the next $ATHX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHX

    DatePrice TargetRatingAnalyst
    11/19/2021$1.25Buy → Neutral
    B of A Securities
    11/19/2021Buy → Neutral
    BofA Securities
    More analyst ratings

    $ATHX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

    Athersys, Inc. (OTC:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analysis of Phase 3 MASTERS-2 clinical trial studying MultiStem for treatment of ischemic stroke indicating additional patients would need to be added to the trial to achieve statistical significance with a primary endpoint of mRS Shift Analysis at Day 365. Completed warrant exercise inducement generating gross proceeds of $3.

    11/16/23 8:30:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

    Athersys, Inc. (NASDAQ:ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distress syndrome ("ARDS") global license. On October 11, 2023, Athersys entered into a warrant exercise inducement offer letter (the "Inducement Letter") with a holder of certain existing warrants ("Holder") to receive new warrants

    10/16/23 4:52:00 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

    The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company's ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified. Because the s

    10/10/23 8:30:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Hansen Maia covered exercise/tax liability with 67 shares, decreasing direct ownership by 0.10% to 70,010 units (SEC Form 4)

    4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

    12/21/23 11:37:15 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hansen Maia covered exercise/tax liability with 23,149 shares, decreasing direct ownership by 25% to 70,144 units (SEC Form 4)

    4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

    10/6/23 5:34:28 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Camardo Daniel A. covered exercise/tax liability with 19,993 shares, decreasing direct ownership by 7% to 285,341 units (SEC Form 4)

    4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

    10/6/23 5:28:22 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Athersys downgraded by B of A Securities with a new price target

    B of A Securities downgraded Athersys from Buy to Neutral and set a new price target of $1.25

    11/19/21 8:21:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys downgraded by BofA Securities

    BofA Securities downgraded Athersys from Buy to Neutral

    11/19/21 7:12:53 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    SEC Filings

    View All

    Athersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ATHERSYS, INC / NEW (0001368148) (Filer)

    1/8/24 7:31:19 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Athersys Inc.

    25-NSE - ATHERSYS, INC / NEW (0001368148) (Subject)

    12/27/23 9:01:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

    8-K - ATHERSYS, INC / NEW (0001368148) (Filer)

    12/22/23 5:09:11 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    Leadership Updates

    Live Leadership Updates

    View All

    Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

    Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings. Dr. Mayhugh currently serves as the Founder and Managing Partner of Wave Strategy, a consultancy focused on the rapid commercialization of healthcare innovations. Under her leadership, Wave Strategy has bridged early-stage t

    8/11/23 8:00:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Murchinson Issues Letter to Fellow Shareholders Regarding the Urgent Need for Boardroom Change at Nano Dimension

    Believes the Stern-Controlled Board's Decision to Challenge Our Special Meeting Demand – Without Any Valid Justification – Reinforces the Need for Objective and Independent Perspectives in the Boardroom Contends the Company is Making Misleading Claims About Murchinson to Distract from Mr. Stern Having Presided Over a More Than 77% Share Price Decline Since Becoming Chairman Puts Forward Proposals to Remove Four Incumbents and Appoint Two Highly Qualified, Independent Director Candidates with Sorely Needed Capital Allocation Acumen and Corporate Governance Expertise Sees a Clear Opportunity to Optimize Nano Dimension's Overcapitalized Balance Sheet, Explore Strategic Options to Maximize V

    2/2/23 5:25:00 PM ET
    $ATHX
    $IMMR
    $NNDM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer peripheral equipment
    Technology

    Athersys Appoints Joseph Nolan to Its Board of Directors

    Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph "Joe" Nolan to its Board of Directors, effective January 4, 2023. Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent. "Joe is a strong addition to our Board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations. His understanding of th

    1/5/23 4:33:00 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    Financials

    Live finance-specific insights

    View All

    Athersys to Host Business Update Conference Call on August 9th

    Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke. Date

    7/31/23 1:38:00 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys to Host Business Update Conference Call on April 20th

    Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss upcoming milestones supporting the pivotal Phase 3 ischemic stroke trial, MASTERS-2. Date April 20, 2023 Time

    4/10/23 3:29:00 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athersys to Host Business Update Conference Call on February 14th

    Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress, upcoming milestones and vision for the year. Date February 14, 2023 Time 11:00 a.m. (Eastern Time) Live webcast re

    2/2/23 8:30:00 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Athersys Inc.

    SC 13G - ATHERSYS, INC / NEW (0001368148) (Subject)

    7/8/22 4:57:01 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Athersys Inc. (Amendment)

    SC 13G/A - ATHERSYS, INC / NEW (0001368148) (Subject)

    2/9/22 3:24:54 PM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Athersys, Inc. (Amendment)

    SC 13D/A - ATHERSYS, INC / NEW (0001368148) (Subject)

    9/21/21 9:14:13 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care